Influence Of Enhanced Bioavailable Curcumin On Obesity-associated Cardiovascular Disease Risk Factors And Arterial Function: A Double-blinded, Randomized, Controlled Trial
Notes for this study:
||RHI. Placebo: before 2.08 ± 0.16, after 1.90 ± 0.15. Curcumin: before 2.02 ± 0.16, after 1.99 ± 0.22.
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 22 obese but healthy, male participants were assigned to take 193.0 mg of curcuminoids infused into 60% soluble fiber from fenugreek, or the fenugreek fiber alone, daily, for 12 weeks.
There was a statistically significant reduction for the curcumin group in homocysteine and an increase in HDL compared with placebo. There was no statistically significant difference between groups at the end of 12 weeks for fasting glucose, insulin, leptin, adiponectin, antioxidant capacity as assessed by uric acid equivalents or copper reducing equivalents, LDL, or any measure of endothelial function or blood pressure.
No adverse events were reported.